About: Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Creator	Hasan, Mahmudul Al, Abdullah Dash, Raju Hannan, Abdul Hossain, \| Khan, Kawsar Khatun, Amena Md, \| Rahman, Sadaqur Sohag, Mamun Uddin, Jamal
Source	Medline; PMC
abstract	Coronavirus disease‐19 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID‐19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS‐CoV‐2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target‐based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti‐SARS‐CoV‐2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS‐CoV‐2 infection.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1002/ddr.21709
bibo:pmid	32632960
has license	no-cc
sha1sum (hex)	75f451d35a7d36442711d53d26149470a111ad11
schema:url	https://doi.org/10.1002/ddr.21709
resource representing a document's title	Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
has PubMed Central identifier	PMC7361641
has PubMed identifier	32632960
schema:publication	Drug Dev Res
resource representing a document's body	covid:75f451d35a7d36442711d53d26149470a111ad11#body_text
is schema:about of	named entity 'effective' named entity 'targets' named entity 'therapeutics' named entity 'THERAPEUTICS' named entity 'POSSIBLE' named entity 'DISEASES IN HUMAN' named entity 'ACCELERATE' named entity 'CONTAGIOUS DISEASES' named entity 'WORKING' named entity 'THERAPEUTIC' named entity 'potential' named entity 'agent' named entity 'therapeutics' named entity 'repurposing' named entity 'Coronavirus' named entity 'discovery' named entity 'vital' named entity 'develop' named entity 'comprehensive' named entity 'targets' named entity 'SARS-CoV-2' named entity 'vaccines' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'Coronavirus disease' named entity 'drug discovery' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'druggable' named entity 'hydrolyzed' named entity 'helicase' named entity 'PLpro' named entity 'atomization' named entity 'Peking University' named entity 'infection' named entity 'infection' named entity 'Ruijin Hospital' named entity 'adverse effects' named entity 'proteases' named entity 'coronavirus' named entity 'nucleocapsids' named entity 'ACE2' named entity 'pathogenesis' named entity 'C-terminal' named entity 'COVID' named entity 'ACE2' named entity 'mesylate' named entity 'chymotrypsin-like' named entity 'Siltuximab' named entity 'animal models' named entity 'arboviruses' named entity 'lung' named entity 'GM-CSF' named entity 'antiviral drugs' named entity 'peptides' named entity 'vaccine' named entity 'preclinical' named entity 'COVID-19 disease' named entity 'polypeptide' named entity 'viral entry' named entity 'N-terminal domain' named entity 'COVID' named entity 'chloroquine' named entity 'ACE2' named entity 'protein' named entity 'mumps' named entity 'SARS-CoV' named entity 'cation' named entity 'Ritonavir' named entity 'Wrapp' named entity 'intravenous administration'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software